The primary therapeutic utility of В-КАР is commonly used in therapeutic domains involving certain distressing symptoms, contributing to supportive management and patient benefit. The medication is relevant for easing symptoms associated with two main condition categories: pulmonary arterial hypertension (PAH) and erectile dysfunction (ED).

Supporting Physical Capacity in Pulmonary Arterial Hypertension

This medication is applied in the long-term management of PAH, a condition marked by symptoms related to systemic imbalance, such as fatigue and shortness of breath with exertion. The therapeutic benefit contributes to improved comfort during periods of heightened symptoms by easing the strain on the heart and improving the patient’s ability to engage in daily physical activities, and is considered relevant for easing the overall symptom load associated with this progressive condition.

Facilitating Vascular Response for Erectile Dysfunction

В-КАР is applied in the symptomatic management of ED, addressing symptoms linked to organ-specific functional stress, specifically the inability to achieve or sustain an erection firm enough for satisfactory sexual intercourse. It is commonly used to help with ED arising from physical or organic causes.

“The core use is to provide support that helps ease the overall symptom burden linked to two distinct forms of vascular function impairment.”

The main therapeutic benefit is the practical support provided, which ultimately assists with supporting functional stability during symptomatic periods and contributes to improved day-to-day comfort and supports general well-being for adult men.

---

Quick Fact: Supports Management of Cardiopulmonary and Urological Symptoms

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use В-КАР? (Sildenafil)

The eligibility for using В-КАР is strictly defined by regulatory authorities based on specific patient populations and existing health conditions.

Populations Prohibited From Use (Contraindications): Use is absolutely prohibited for individuals taking organic nitrates or nitric oxide donors (due to severe hypotension risk) and those taking guanylate cyclase stimulators (e.g., riociguat). The medicine is also contraindicated in patients with severe hepatic impairment, a recent history of stroke or myocardial infarction, uncontrolled hypotension (blood pressure below 90/50 mmHg), or a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).

Age and Conditional Use: For the Erectile Dysfunction (ED) indication, use is restricted to men aged 18 years and older. For Pulmonary Arterial Hypertension (PAH), the medicine is approved for adults and children one year of age and older, though use in children carries regulatory safety warnings. Patients with severe renal impairment should receive a lower starting dose. Caution is required for patients with conditions predisposing to priapism (e.g., sickle cell anemia) or active bleeding disorders. Use during pregnancy or lactation is generally not recommended unless the benefit for PAH is determined to outweigh the potential risks, as adequate studies are lacking.

Interactions with Other Medicines and Products

This section outlines the clinically significant interactions of V-KAR as documented in authoritative regulatory labeling. Interactions are classified based on their potential to alter drug exposure or cause additive pharmacodynamic effects.

---

Contraindicated Combinations and Significant Restrictions

Co-administration with strong CYP3A4 inducers (e.g., rifampin, phenytoin) is contraindicated due to the risk of a severe decrease in V-KAR exposure, which may lead to loss of therapeutic effect. The consumption of grapefruit juice and co-administration with the herbal product St. John's Wort are also restricted because they significantly alter V-KAR plasma levels.

---

Pharmacokinetic and Pharmacodynamic Interactions

V-KAR exposure is substantially increased when administered with strong CYP3A4 inhibitors (e.g., ketoconazole, cyclosporine). This increase is due to V-KAR being a substrate for both the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. V-KAR is also documented as a moderate inhibitor of CYP2D6, potentially increasing the concentrations of co-administered CYP2D6 substrates.

Pharmacodynamic interactions include an increased risk of additive effects on cardiac repolarization when co-administered with other QT-prolonging agents.

---

Administration and Population Notes

Administration requires a minimum separation of two hours from polyvalent cation-containing antacids to prevent impaired absorption. The magnitude of certain interactions may be amplified in patients with severe hepatic impairment due to reduced baseline clearance, as documented in clinical pharmacology studies.

Selective Inhibition of the PDE5 Enzyme

The mechanism of В-КАР begins with the selective competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme. This enzyme normally catalyzes the rapid breakdown of the intracellular messenger, cyclic Guanosine Monophosphate (cGMP), which is essential for initiating smooth muscle relaxation. By blocking the PDE5 enzyme, В-КАР acts within domains involving enzyme-mediated signaling and results in a prolonged biochemical signal.

Potentiation of the NO/cGMP Vascular Pathway

The preservation of cGMP potentiates the natural signal generated by Nitric Oxide (NO) release within the vascular system. The elevated cGMP concentration triggers a signaling cascade that reduces the tension in the vascular smooth muscle surrounding arteries. This physiological change results in local vasodilation—the widening of blood vessels—leading to an increase in localized blood flow and tissue perfusion.

️ Functional Constraint: Absolute NO Dependence

This mechanism is solely a potentiator of the natural NO/cGMP pathway and cannot initiate the process independently. The resulting physiological effects, such as localized vasodilation and increased blood flow, are entirely conditional upon the prior, physiological release of NO. Furthermore, the molecule exhibits limited off-target activity on other PDE subtypes (e.g., PDE6), which can introduce non-primary physiological consequences.

How to Use В-КАР: Administration Guidelines

В-КАР (Sildenafil) is administered based on regimens that detail distinct protocols for its two primary indications. The medicine is available for oral administration (as tablets or an oral suspension) and, in certain clinical contexts for Pulmonary Arterial Hypertension (PAH), as an Intravenous (IV) injection.

Official Dosing Regimens

Indication	Starting Dose	Maximum Frequency / Daily Limit
Erectile Dysfunction (ED)	50 mg (as needed)	Once per day (maximum 100 mg)
Pulmonary Arterial Hypertension (PAH)	20 mg (three times a day, TID)	80 mg TID (Maximum oral dose)

Timing and Conditions of Use

For ED, the medicine is used on-demand approximately 1 hour before activity, though it can be taken between 30 minutes and 4 hours prior. A maximum of one dose may be taken in any 24-hour period. For PAH, the administration is continuous and long-term, with doses taken at fixed intervals, approximately 4 to 6 hours apart.

The medicine may be taken with or without food. However, for ED, taking the tablet with a high-fat meal may delay the onset of its activity.

Population-Specific Adjustments

Clinical guidelines describe considering a lower starting dose of 25 mg for the treatment of ED in certain populations. This includes older adults (ge 65 years of age) and patients with severe renal or hepatic impairment.

Research evidence / Overview of studies

This section summarizes key research that has investigated the drug in patients with chronic joint pain.

---

Core Efficacy Studies

Research explored the drug's activity. Studies have also examined the effect on symptoms.

Studies evaluated whether the drug affected mobility and morning stiffness. A key study reported on the changes in pain scores over a 12-week period.

Research also examined whether the drug affected the need for rescue medication. The drug was investigated as a treatment for moderate-to-severe pain.

This information describes what studies examined and is not a substitute for medical discussion.

---

Study Design and Findings

Researchers indicate that most data comes from randomized, placebo-controlled trials (RCTs). These studies followed patient groups for up to 6 months.

Research has compared the outcomes of the drug to placebo regarding joint swelling. Researchers have studied the drug's effects on persistent pain.

Studies monitored the common side effects and safety profile of the drug in adults. Research protocols noted specific administration conditions.

Key Studies & References Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA (Article reviewing NAVIGATE trials and regulatory decision)

Common questions about В-КАР (FAQ)

Q: What is В-КАР used for?

В-КАР is a prescription medication indicated for the management of certain heart conditions, including specific types of arrhythmia and chronic stable angina pectoris. It is also approved for use in reducing the risk of cardiovascular events in certain patient populations.

Q: How does В-КАР work?

В-КАР is classified as a beta-blocker. Its action involves affecting the body's response to certain nerve impulses, primarily in the heart, which may help to slow the heart rate and reduce blood pressure. Research suggests that its mechanism contributes to the intended therapeutic effects.

Q: What are the potential side effects of taking В-КАР?

Like all medications, В-КАР may be associated with side effects. Commonly reported effects in clinical trials include fatigue, dizziness, and cold extremities. Less common but more serious effects have been reported. It is important to discuss all potential side effects and personal medical history with a healthcare provider.

Q: Is В-КАР safe for everyone?

В-КАР is generally not recommended for individuals with specific pre-existing health conditions, such as certain severe heart rhythm disorders or uncontrolled heart failure. Safety is determined by a physician based on a complete assessment of the patient's medical history and current health status. Never stop or start a medication without consulting a doctor.

How to Store and Dispose of В-КАР

В-КАР (Sildenafil) tablets must be stored at controlled room temperature, specifically between 20 mathrmC and 25 mathrmC (68 mathrmF and 77 mathrmF). It is essential to protect the medication from excessive heat and moisture.

Storage and Handling Rules

The product must be kept in the original container and the container must remain tightly closed to maintain product stability. As a mandatory requirement, В-КАР must be stored out of the reach of children to prevent accidental ingestion.

Official Disposal Instructions

Disposal of unused or expired tablets must comply with local pharmaceutical waste requirements. Regulatory documents explicitly state that the medicine must not be thrown away via household waste or flushed down the toilet.